MEDICAL DEVICES PROGRAMME
|
|
- Marylou Berry
- 6 years ago
- Views:
Transcription
1 MEDICAL DEVICES PROGRAMME 3-4 October 2017 Medical Devices Symposium, updated 29August 2017, external Page 1
2 Working Party Margareth Jorvid LSM Group, Sweden (Chair) Michael Kipping MHRA, UK Janine Jamieson JCombinations AB, Sweden Tim Chesworth AstraZenenca, UK Gert Bos, Qserve Group BV, the Netherlands Nick Baker LRQA, UK Theresa Jeary LRQA, UK Medical Devices Symposium, updated 29August 2017, external Page 2
3 Tuesday 3 October 2016 Medical Devices Symposium Registration, exhibition and refreshments Introduction to Medical Devices Symposium Margareth Jorvid Methra Uppsala AB, LSM Group, Sweden Medical Devices Symposium, updated 29August 2017, external Page 3
4 SESSION 1: Optimising the implementation of the new MDR Leader: Margareth Jorvid Methra Uppsala AB, LSM Group, Sweden An overview of the future regulatory framework and the key changes in the new Medical Device Regulation (MDR). What will their impact be on industry and how can organisations best prepare to deliver the new requirements within the timelines? Chair: Margareth Jorvid Methra Uppsala AB, LSM Group, Sweden Introduction The new Medical Device Regulation Erik Hansson Deputy Head of Unit, Directorate General for Internal Market, Industry, Entrepreneurship and SMEs, Health Technology and Cosmetics, European Commission The new MDR What does the new Regulation include? Timelines for implementation Development of guidelines Implementation challenges, how to prepare Céline Bourguignon Director Global Regulatory Policy, Johnson and Johnson, Belgium Consequences for industry Preparation Transition period Panel discussion: How to work together moderated by Margareth Jorvid This session s speakers and speakers from Session 2 (Notified Body + Competent Authority) will take questions from the floor Lunch in Exhibition Hall Medical Devices Symposium, updated 29August 2017, external Page 4
5 SESSION 2: Implications of new regulatory oversight requirements Leader: Gert Bos, Qserve Group BV, the Netherlands The new MDR changes supervision requirements both for notified bodies (NBs) and competent authorities (CAs). There are changes to setting up as an NB, conformity assessment routes and methods of practice. For CAs there are more specific requirements on supervision of NBs, market surveillance, and formulating and approving delegated and implementing acts, as well as common specifications. Chair: Gert Bos Qserve Group BV, the Netherlands Introduction In recent years, additional instructions and guidance to notified bodies have been issued, resulting in stricter conformity assessment routes. In addition, the 2016 publication of the MEDDEV 2.7/1 rev.4 guidance on clinical evaluation has further enhanced the expectations to keep products on the market. Key players from CAs and NBs will explore their new level of expectations, and will provide guidance and explanations to the audience Impact on Notified Body Bassil Akra Vice President Global Focus Teams Cardiovascular, Orthopedic and Clinical, TUEV SUED Product Service, Germany Important steps towards a successful notification according to the new Regulation Impact of the guidance document on the medical device manufacturer portfolio New duties of the notified bodies during the approval process and post-market surveillance activities Impact on Competent Authority John Wilkinson Director of Devices Division, MHRA, UK New responsibilities for competent authorities Expanded or more specific extensions to current responsibilities Role of CAs in more complex set of necessary collaborations across the system and the product lifecycle Panel discussion moderated by Gert Bos This session s speakers and speakers of Session 1 (Commission + Industry) will take questions from the floor Break End of Session 2 Medical Devices Symposium, updated 29August 2017, external Page 5
6 SESSION 3: Embracing the digital healthcare revolution Leader: Tim Chesworth, AstraZeneca, UK The effective use of apps, connected devices and other digital support services has the potential to have a profound and positive impact on patient outcomes. Regulators recognise this and are trying to adapt in a rapidly changing technological environment. Where do regulators and industry need to collaborate further to ensure patients can realise digital health benefits in a timely but safe and controlled manner? Chair: Tim Chesworth, AstraZeneca, UK Introduction The future and challenges of software regulation Valerie Field Head of Devices Software/apps, Devices, MHRA, UK Pace of new technology Challenges for Regulation Future guidance Industry challenges with medical device software Kirsten Paulson Pfizer, US Development costs and timelines Change control across countries and over time MDR implementation Releasing software every week in a regulated environment David Hubanks Propeller Health, US Agile development overview Mapping agile to ISO & 21 CFR 820 Practical results (and the danger of too many doughnuts) Improvement paths & next steps Panel discussion moderated by Tim Chesworth This session s speakers will take questions from the floor End of Session 3 Delegates move to Human Medicines Symposium TOPRA Board update and student poster winners announced Networking drinks in exhibition hall followed by freedom to explore London Medical Devices Symposium, updated 29August 2017, external Page 6
7 Margareth Jorvid LSM Group, Sweden Wednesday 4 October 2017 Session 4: [Combined Human Medicines and Medical Devices] Medicinal products incorporating device components significant change ahead Leader: Janine Jamieson JCombinations AB, Sweden The new Medical Device Regulation will amend medicines regulation to involve notified bodies in review of medicinal products incorporating integral medical devices. At the same time, the EMA is proposing a guideline on Quality requirements of medicinal products containing a device component for delivery or use of the medicinal product, highlighting the increasing importance of such combinations in healthcare treatments. Chair: Janine Jamieson JCombinations AB, Sweden Introduction EMA perspective on increasing focus on review of device components of medicinal products Armin Ritzhaupt Regulatory Affairs Officer, EMA Update from CHMP QWP/BWP draft Concept Paper on developing guidance on Quality of drug device combination products The new Medical Device Regulation amending medicines legislation to require review by notified bodies for some integral device components role and responsibilities of EMA Experience from reviews of medicinal products incorporating device components and collaborations with notified bodies Notified body perspective and advice on when and how to engage notified bodies Theresa Jeary LRQA, UK Current reviews of drug delivery devices for conformity with safety and performance requirements How will review of integral devices differ from current procedures? Advice for pharma and device manufacturers on timelines and data expectations for notified body assessment Global perspective update from the FDA Office of Combination Products, including working with other regions towards harmonisation of requirements FDA speaker invited Current focus on combination and complex products at the FDA Combination products Policy Council and the intercenter consult process pilot building relationships between drug and device reviewers FDA Final Rules and Guidances on cgmp and Post-market Combination Product Safety Reporting. Medical Devices Symposium, updated 29August 2017, external Page 7
8 10.05 Panel discussion moderated by Janine Jamieson The speakers will take questions from the floor with invited panelist Elizabeth Baker, Group Manager Licensing Division, MHRA, UK Break Medical Devices Symposium, updated 29August 2017, external Page 8
9 SESSION 5: [Combined Human Medicines and Medical Devices] Personalised medicine: In vitro diagnostics and companion diagnostics Leader: Nick Baker LRQA, UK A look at the new In Vitro Diagnostics (IVD) Regulation and its potential impact on industry, eg, under the new classification and conformity assessments most IVD assays will be reviewed by a notified body. Companion diagnostics also have their own particular conformity assessment requirements requiring notified bodies to consult either with the EMA or competent authorities. How will this work in practice for pharmaceutical and diagnostics manufacturers? Chair: Nick Baker Technical Manager, LRQA, UK Introduction An overview of the new In Vitro Diagnostics Regulation (IVDR) Nick Baker LRQA, UK New classification system Consultation process Workload challenges Competent authority perspective Daryl Colombage - Senior Medical Device Specialist, MHRA, UK IVDR and companion diagnostics Performance studies and evaluation Current situation Challenges for industry Peter Martin Roche Diagnostics Panel discussion moderated by Nick Baker, with this session s speakers and invited panelist Armin Ritzhaupt, Regulatory Affairs Officer, EMA, taking questions from the floor Light lunch Continue in Human Medicines Symposium: SESSION 6: UK Exit From the EU Leader: David Jefferys, Eisai Medical Devices Symposium, updated 29August 2017, external Page 9
10 The impact of the UK s decision to leave the EU will be significant for the pharmaceutical and medical devices industry as well as the EMA and the MHRA. The process to withdraw will be complex and will take at least two years to complete. Although the final outcomes are as yet unknown, this session will consider preparations being made by the MHRA and EMA. Potential impacts on the UK and European industries will also be discussed in the light of emerging scenarios. Chair: David Jefferys Senior Vice President, Eisai, UK Introduction David Jefferys Senior Vice President, Eisai, UK What is known to date and what is still to be determined MHRA preparations made to date and the process for future discussions Jonathan Mogford Director of Policy and Andy Gregory Head of EU, International Policy and Strategy, MHRA An overview of preparations the MHRA has made to date, given the remaining uncertainties. To provide the audience with information on what process and communication from the MHRA can be anticipated in the coming months How the EMA is preparing and what has been decided so far Noel Wathion Deputy Executive Director, EMA Pharmaceutical industry views and the possible future impact for the pharmaceutical industry Virginia Acha Executive Director Research, Medical & Innovation, The Association of the British Pharmaceutical Industry (ABPI), UK Medical device industry views and the possible future impact for the devices industry Neil R Armstrong CEO, MeddiQuest, UK Panel discussion moderated by chair This session s speakers will take questions from the floor Closing remarks by MHRA Close of Symposium by TOPRA President End of Symposium Medical Devices Symposium, updated 29August 2017, external Page 10
Update on Regulation of Drug/Device Combination Products Europe and Beyond. Janine Jamieson, Editorial Staff Europe, IPQ Publications
Update on Regulation of Drug/Device Combination Products Europe and Beyond Janine Jamieson, Editorial Staff Europe, IPQ Publications Outline new regulations, guidance, initiatives and conferences.. Background
More informationThe new EU Regulations on medical devices and first steps of their implementation
The new EU Regulations on medical devices and first steps of their implementation TOPRA Annual Medical Devices Symposium 2017 London, 3 October 2017 Erik HANSSON Deputy Head of Unit Health Technology and
More informationA regulatory update in a day for Small to Medium-sized Enterprises
TOPRA ANNUAL SYMPOSIUM STOCKHOLM, SWEDEN In partnership with the Swedish Medical Products Agency Time of transformation: Implementing international regulatory change A regulatory update in a day for Small
More informationThe implications of the new EU Medical Device Regulation on Combination Product Packaging
The implications of the new EU Medical Device Regulation on Combination Product Packaging ANDREW LOVE VP Capability Development Be4ward Ltd Introduction Be4ward Andrew Love www.andrewrlove.com A niche
More informationThe implications of the new EU Medical Device Regulation on Combination Product Packaging
The implications of the new EU Medical Device Regulation on Combination Product Packaging June 2017 ANDREW LOVE VP Capability Development Be4ward Ltd Introduction Be4ward Andrew Love www.andrewrlove.com
More informationMaking the case for Personalised Medicine
Making the case for Personalised Medicine The biopharmaceutical industry perspective Barbara Freischem Executive Director European Biopharmaceutical Enterprises Who we are EBE represents the voice of biopharmaceutical
More informationPerspective: New European IVD Regulations New Concepts for Market Authorizations and Product Launch Schedules
Perspective: New European IVD Regulations New Concepts for Market Authorizations and Product Launch Schedules Planning for Efficiencies of Data, Resources, and Timelines A PRECISION BRIEF Introduction
More informationRecast Medical Device directives Impacts on materiovigilance
Recast Medical Device directives Impacts on materiovigilance Journée Vigilance 23.03.2017 Valérie Nys Revision of the EU Medical Devices Legislation Directive 90/385/EEC on active implantable medical devices
More informationThe Medical Device Coordination Group: a new Authority Under EU Device Regulations
The Medical Device Coordination Group: a new Authority Under EU Device Regulations By Robert D. Cumming and Nancy W. Mathewson, Esq. This article discusses the organization and functions of the Medical
More informationEUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY
EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY Health systems, medical products and innovation Medicines: policy, authorisation and monitoring STAMP 4/24 Record STAMP Commission Expert
More informationGlobal regulator and industry activities on drug/device combination products - focus on Europe
Global regulator and industry activities on drug/device combination products - focus on Europe Janine Jamieson, Editorial Staff Europe, IPQ Publications CASSS EU Forum, May 2016, Paris Current positive
More informationDeveloping the next generation of. regulatory affairs professionals: A. certified training programme. TOPRA Symposium 2017 Professional Development
TOPRA Symposium 2017 Professional Development Developing the next generation of regulatory affairs professionals: A certified training programme Dr Samantha Alsbury, Head of Professional Development, TOPRA
More informationImpact of the IVD Regulations. Barbara Fallowfield Managing Director
Impact of the IVD Regulations Barbara Fallowfield Managing Director What will I cover today? Timelines Key Changes Classification Clinical Evidence Requirements Third Parties Vigilance and Post Marketing
More informationAssuring data integrity; best practice
Assuring data integrity; best practice Royal Society of Chemistry, Burlington House, Piccadilly, London W1J 0BA Thursday 16th March 2017 Data integrity is receiving much attention in the pharmaceutical
More informationInterface between medicinal product and medical devices development - Update on EMA implementation of the new medical devices legislation
Interface between medicinal product and medical devices development - Update on EMA implementation of the new medical devices legislation Combined medicines and devices developments SME info day, 26 October
More informationIntroduction to the new regulatory framework for medical devices and in vitro diagnostic medical devices
Introduction to the new regulatory framework for medical devices and in vitro diagnostic medical devices Vincent Houdry DG for Internal Market, Industry, Entrepreneurship and SMEs European Commission Key
More informationThe upcoming EU MDR. Gert Bos. - key changes overview. Executive director & Partner. ..the practical approach
The upcoming EU MDR - key changes overview Gert Bos Executive director & Partner A global leading medical device consultancy group Europe - Amsterdam (HQ) USA - Boston - San Francisco China Nanjing Copyright
More information2 DAY WORKSHOP on Preparing For The New EU Medical Device Regulations (MDR)
WORLD COMPLIANCE SEMINARS SPEAKER:- DAVID R DILLS Regulatory Affairs & Compliance Consultant 2 DAY WORKSHOP on Preparing For The New EU Medical Device Regulations (MDR) 21-22, FEB- 2018 Burlingame CA Course
More information2 DAY WORKSHOP on Preparing For The New EU Medical Device Regulations (MDR)
WORLD COMPLIANCE SEMINARS SPEAKER:- DAVID R DILLS Regulatory Affairs & Compliance Consultant 2 DAY WORKSHOP on Preparing For The New EU Medical Device Regulations (MDR) 21-22, FEB- 2018 Burlingame CA Course
More informationDisclosures. Laboratory Stakeholders. IVD vs. LDT. FDA Regulation of Laboratory Developed Tests 10/2/2015. FDA Regulation of LDTs
Disclosures FDA Regulation of Laboratory Developed Tests Beaumont Health System, 24 th Annual Symposium on Molecular Pathology September 16, 2015 Roger D. Klein, MD JD Director, Molecular Pathology Clinical
More informationManufacturers of in vitro Diagnostic
European Commission Factsheet for Manufacturers of in vitro Diagnostic Medical Devices This Factsheet is aimed at manufacturers of in vitro diagnostic medical devices. For information on the impact of
More informationManufacturers of In-Vitro Diagnostic
Ref. Ares(2018)3873780-20/07/2018 Factsheet for Manufacturers of In-Vitro Diagnostic Medical Devices This Factsheet is aimed at manufacturers of in-vitro diagnostic medical devices. For information on
More informationInvestigational New Drug (IND) & Investigational Device Exemptions (IDE) Applications Preparation and Submission, and Conducting FDA Meetings
Investigational New Drug (IND) & Investigational Device Exemptions (IDE) Applications Preparation and Submission, and Conducting FDA Meetings Submissions to a regulatory agency involve more than just writing
More informationRegulatory Information Management
Regulatory Information Management Hotel Meliá Avenida América, Madrid http://www.reginfomanagement.com/ Day 1 - Tuesday 26 April 2016 08:30-09:00 Conference Registration 09:00-09:10 Opening remarks from
More informationInvestigational New Drug (IND) & Investigational Device Exemptions (IDE) Applications Preparation and Submission, and Conducting FDA Meetings
Investigational New Drug (IND) & Investigational Device Exemptions (IDE) Applications Preparation and Submission, and Conducting FDA Meetings *** LIMITED TIME OFFER: FREE $100 AMAZON GIFT CARD! *** REGISTER
More informationAbout Arena s Clinical Trial Series Confirmed Speaking Faculty
About Arena s Clinical Trial Series The Clinical Trials Conference series launched over a decade ago and now runs in more than 14 locations worldwide. The acclaimed series is a platform for biopharmaceutical
More information11/12/2018. Shaping the Future Together UK R&D Leadership Community in the NHS. Agenda. Phase 2 Clinical Trials UK vs Global
Shaping the Future Together R&D Leadership Community in the NHS Implications of Brexit for Clinical Research Agenda Commercial Clinical Trials in the Pharmaceutical Industry Priorities for Brexit Where
More informationRegulatory Framework for Medical Device
Regulatory Framework for Medical Device International Seminar Safety of Health Products French Ministry of Labour, Employment and Health Paris, 26 May 2011 Peter Bischoff-Everding European Commission EU
More informationCAREER DEVELOPMENT FOR EXPERIENCED REGULATORY PROFESSIONALS
CAREER DEVELOPMENT FOR EXPERIENCED REGULATORY PROFESSIONALS How TOPRA can support you as you drive your regulatory career forward ABOUT TOPRA TOPRA (The Organisation for Professionals in Regulatory Affairs)
More informationThe 24 th Autumn Introductory Course: Target the Heart of European Regulatory Affairs *Preliminary Programme
The 24 th Autumn Introductory Course: Target the Heart of European Regulatory Affairs *Preliminary Programme Prague, Czech Republic Vienna House Andel s Prague Stroupeznickeho 21, 15000 Prague, Czech Republic
More informationANNUAL SYMPOSIA AMSTERDAM PROGRAMME 2016
ANNUAL SYMPOSIA AMSTERDAM PROGRAMME 2016 Human Medicines Medical Devices SME Day Parallel Sessions 28 30 September 2016 Hilton Amsterdam Hotel Apollolaan 138, Amsterdam, 1077 BG, Netherlands T +31 20 710
More informationABPI response to European Commission consultation on advanced therapy medicinal products
ABPI response to European Commission consultation on advanced therapy medicinal products 28 March 2013 ABPI response to European Commission consultation on the regulation of advanced therapy medicinal
More informationThe 23 rd Autumn Introductory Course:
The 23 rd Autumn Introductory Course: Target the Heart of European Regulatory Affairs Prague, Czech Republic Sheraton Prague Charles Square hotel Zitna 561/8, Prague 13-17 November 2017 Monday 13 November
More informationStaffing - Medical Devices
Staffing - Medical Devices LONDON GENEVA SINGAPORE DUBLIN procorre.com 1 Implementing solutions to clients worldwide 2 Contents Services 04 Sector Overview 07 Medical Devices 07 In-Vitro Diagnostics 08
More informationComparative Overview of Other Medical Devices Regulatory Systems
Comparative Overview of Other Medical Devices Regulatory Systems Dr David Jefferys, BSc MD, FRCP, FFPM Medical Device Expert Senior Vice President Global Regulatory, Healthcare Policy and Corporate Affairs
More informationPublic Consultation on Annual Review and Proposal for Fees For Financial Year Medical Devices
Public Consultation on Annual Review and Proposal for Fees For Financial Year 2018 Medical Devices 8th May 2018 CONTENTS 1 INTRODUCTION 3 2 REVIEW OF THE 2017 FEES 3 2.1 The 2017 fees 3 2.2 The 2018 fees
More informationCourse Title ID Duration Basic Premium. Biological Evaluation of Medical Devices: A Risk-Based Approach N mins
Pre-Clinical Basic Level : CMDA Certified Medical Device Associate Biological Evaluation of Medical Devices: A Risk-Based Approach N134 63 mins 186.00 144.00 Introduction to Process Validation N135 75
More informationSelf-Care Medical Devices Framework. Dr. Simone Breitkopf Head HEOR, Governmental and Public Affairs
Self-Care Medical Devices Framework Dr. Simone Breitkopf Head HEOR, Governmental and Public Affairs Disclaimer The view and opinions expressed in the following PowerPoint slides are those of the individual
More informationRegulatory Affairs in Medical Technology
Regulatory Affairs in Medical Technology Medical Device Regulation: Implementation on European Level, First Results Dr. Matthias Neumann Federal Ministry of Health Lübeck 2018 Summer Academy on Medical
More informationAbout Arena s Clinical Trial Series Confirmed Speaking Faculty
About Arena s Clinical Trial Series The Clinical Trials Conference series launched over a decade ago and now runs in more than 14 locations worldwide. The acclaimed series is a platform for biopharmaceutical
More information2019 PDA Biosimilars and Vaccines Conference: Lifecycle Similarities and Challenges Thursday, May 9 Registration Open Continental Breakfast
2019 PDA Biosimilars and Vaccines Conference: Lifecycle Similarities and Challenges End-to-End Product Development Manufacturing, Supply, and Quality May 9-10, 2019 Hilton Long Beach Long Beach, CA As
More information2019 PDA Biosimilars and Vaccines Conference: Lifecycle Similarities and Challenges Thursday, May 9 Registration Open Continental Breakfast
2019 PDA Biosimilars and Vaccines Conference: Lifecycle Similarities and Challenges End-to-End Product Development Manufacturing, Supply, and Quality May 9-10, 2019 Hilton Long Beach Long Beach, CA As
More informationRBM Risk Based Monitoring GCP Training 12/SEP/2015. Gabor Kiss Synexus Hungary2015
RBM Risk Based Monitoring GCP Training 12/SEP/2015 Gabor Kiss Synexus Hungary2015 Agenda Why traditional monitoring must change? The landscape Regulatory Industry IT What can we expect? Transition period
More informationRecent Trends in Companion Diagnostic Test Development Partnerships
Recent Trends in Companion Diagnostic Test Development Partnerships Andrew S. Thompson, PhD, Director of Therapy and Analysis, GlobalData Medical, London Tyler Fletcher, Global Head, GlobalData Medical,
More informationEMA perspective on increasing focus on review of device components of medicinal products
EMA perspective on increasing focus on review of device components of medicinal products TOPRA Annual Human Medicines Symposium 2 4 October 2017 - Victoria Park Plaza Hotel, London Presented by Armin Ritzhaupt,
More informationGMP. Safeguard The Patient s Health.
GMP Safeguard The Patient s Health. Scope. Products and testing according to pharma industry standard. Good Manufacturing Practice or GMP are practices and systems that are required to be adapted in pharmaceutical
More informationUpdate on Regulatory Environment- Europe Experience with 2007/47/EC M5 & Discussions on Possible Recast of EU Medical Device Regulations
Update on Regulatory Environment- Europe Experience with 2007/47/EC M5 & Discussions on Possible Recast of EU Medical Device Regulations Paul Brooks Vice President Healthcare, Americas Presentation to:
More informationTOPRA 2020 CHANGE CHALLENGE FUTURE
WHAT WILL HEALTHCARE REGULATORY AFFAIRS LOOK LIKE IN 2020? HOW WILL THE REGULATORY SCIENCE PROFESSION SHAPE THE HEALTHCARE ENVIRONMENT? WHAT WILL HEALTHCARE REGULATORY PROFESSIONALS NEED TO KNOW AND DELIVER
More informationOversight of Laboratory Developed Tests
Oversight of Laboratory Developed Tests APHL Annual Meeting 2015 Indianapolis Alberto Gutierrez, PhD Office of In Vitro Diagnostics and Radiological Health 1 Overview Background IVD regulation Need for
More informationRe: Public Consultation Paper on the Regulation of Advanced Therapy Medicinal Products
ISCT HEAD OFFICE Suite 201 375 West 5 th Avenue Vancouver, BC Canada V5Y 1J6 Tel: 604-874-4366 Fax: 604-874-4378 isct@celltherapysociety.org www.celltherapysociety.org March 30, 2013 European Commission,
More informationCLINICAL TRIAL MANAGEMENT & REGULATORY AFFAIRS in Pharma, Biotech, Medtech Domains
CLINICAL TRIAL MANAGEMENT & REGULATORY AFFAIRS in Pharma, Biotech, Medtech Domains May 10-12, 2016 at EPFL, Odyssea Building, level minus 1, classroom -1 0021 Module Leaders Thomas Girard, Regulatory Affairs
More informationWorkshop on Access to and Uptake of Biosimilar Medicinal Products
Workshop on Access to and Uptake of Biosimilar Medicinal Products A follow-up event to Process on Corporate Responsibility in the Pharma Sector Brussels, 6 October 2015, 10.30am Auditorium, Directorate
More informationComplex Generics: Charting a new path
White paper Complex Generics: Charting a new path Complex generics offer a lucrative market for drug manufacturers, but only if they can adapt to a more complicated and challenging development process.
More informationThe Danish Medicines Agency s strategy for medical devices
låst The Danish Medicines Agency s strategy for medical devices 2017 2021 DECEMBER 2016 Danish Medicines Agency, 2016 This publication may be freely quoted with appropriate acknowledgement of the source.
More informationVALUE OF COMPANION DIAGNOSTICS IN PERSONALISED MEDICINE
VALUE OF COMPANION DIAGNOSTICS IN PERSONALISED MEDICINE Stimulating innovation for improving health through companion diagnostics 5 March 2015 I. Introduction Personalised healthcare provides targeted
More informationGMP for Medical Devices
GMP for Medical Devices NEW: Update regarding EU Medical Device Regulation and ISO 13485 Revision SPEAKERS: Dr Gerhard Bauer Chemgineering Business Design GmbH Harald Rentschler mdc, medical devices certification
More informationCommittees/Working Groups contributing to the implementation of the Medical Device Directives
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE GENERAL Consumer Goods Cosmetics and Medical Devices MEDDEV. 2.15 Rev.3 December 2008 GUIDELINES ON MEDICAL DEVICES Committees/Working Groups contributing
More informationJefferies 2018 Global Healthcare Conference. June 7, 2018
Jefferies 2018 Global Healthcare Conference June 7, 2018 Forward-Looking Statements Statements in this presentation regarding the future financial and operating results, outlook, growth, prospects, business
More information2019 PDA Biosimilars and Vaccines Conference: Lifecycle Similarities and Challenges Thursday, May 9 Registration Open Continental Breakfast
2019 PDA Biosimilars and Vaccines Conference: Lifecycle Similarities and Challenges End-to-End Product Development Manufacturing, Supply, and Quality May 9-10, 2019 Hilton Long Beach Long Beach, CA As
More informationJanuary Summary
The Academy of Medical Sciences and the Royal Academy of Engineering joint response to the Medicine and Healthcare products Regulatory Agency s public consultation on the revision of European legislation
More information8 th STAMP expert group meeting
8 th STAMP expert group meeting Repurposing: Themes & discussion points from case studies Dr Daniel O Connor MHRA (UK) Repurposing medicines Drug repurposing is the process of identifying a new use for
More informationSOPs for FDA-Regulated Industry: Best Practices to Withstand FDA Expectations
SOPs for FDA-Regulated Industry: Best Practices to Withstand FDA Expectations One of the best ways to ensure that an organization meets its regulatory obligations is to follow SOPs. SOPs are standardized
More informationICH Q8/Q8(R)
Pharmaceutical Quality for the 21 st Century Temple University May 06, 2008 Joseph Famulare, Deputy Director FDA CDER Office of Compliance CDER Office of Compliance and the Critical Path Initiative Since
More informationMedical Devices & In-Vitro Diagnostics
Medical Devices & In-Vitro Diagnostics The new EU regulations in a nutshell Robert Geertsma, Senior Scientist, RIVM Robert.Geertsma@rivm.nl Ricco Buitink Team Coordinator Medical Devices MoH NL Content
More informationUpdate on EU regulatory developments
Update on EU regulatory developments Jean-Francois Roche European Commission Health Technology and Cosmetics IMDRF 13 20-22 March 2018 Shanghai, China The EU single market for medical devices 1. EU 2.
More informationDeveloping a Companion Diagnostics in parallel to a medicinal product Legal and Regulatory requirements in Europe and in the US
Developing a Companion Diagnostics in parallel to a medicinal product Legal and Regulatory requirements in Europe and in the US Companion Diagnostics are in vitro diagnostic medical devices device specifically
More information4.0 HEALTHCARE 4.0. The Data Imperative August 2018 Royal Randwick Turf Club, Sydney ANNUAL CONFERENCE MAJOR SPONSOR
HEALTHCARE 4.0 The Data Imperative 21 23 August 201 Royal Randwick Turf Club, Sydney 4.0 MAJOR SPONSOR Professional Development in Therapeutics 4.0 Join us at this year s ARCS Annual Conference Healthcare
More informationMedical Devices Managing Evolving Standards in Multiple Jurisdictions
Medical Devices Managing Evolving Standards in Multiple Jurisdictions Ella Shaw, BSc, Samarind RMS, Application Specialist Dr. Dr. Michel Mikhail, Expert in Global Regulatory Affairs Worldwide Presence
More informationSOPs for FDA-Regulated Industry Best Practices to Withstand FDA Expectations
SOPs for FDA-Regulated Industry Best Practices to Withstand FDA Expectations *** LIMITED TIME OFFER: FREE $100 AMAZON GIFT CARD! *** REGISTER TODAY! One of the best ways to ensure that an organization
More informationCare.data Programme Board Terms of Reference
Document filename: care.data Programme Board Terms of Reference Directorate / Programme Document Reference Care.data Programme Project Programme Director Eve Roodhouse Status Final Owner Eve Roodhouse
More informationISO 13485:2016 Medical Devices-Quality Management Systems- Requirements for Regulatory Purposes. Theresa McCarthy
ISO 13485:2016 Medical Devices-Quality Management Systems- Requirements for Regulatory Purposes Theresa McCarthy Welcome and Introductions Please interview and collect: Name Primary Quality Management
More informationReady or Not: The New Medical Device Regulations Are Here!
Ready or Not: The New Medical Device Regulations Are Here! Felicia R Cochran, PhD, CMPP TM feliciacochran@earthlink.net FR Cochran 1 General Disclaimers This presentation represents the knowledge, professional
More informationUpdated EU Medical Device Regula2ons: What s In, What s Out, and What s Hot?
Updated EU Medical Device Regula2ons: What s In, What s Out, and What s Hot? Introduc2on EU Medical Device Overview Current Medical Device Direc2ves ü Governed by 3 directives (past 15-20 yrs): Polling
More informationPre- ICDRA Exhibition Guide
Pre- ICDRA Exhibition Guide Invitation to Exhibit at PRE- ICDRA 3-4 September 2018 The HPRA is honoured to have been selected by the World Health Organization (WHO) to host delegates from each of the WHO
More informationOutsourcing in Clinical Trials West Coast: Medical Device Stream Burlingame, CA February 22 nd 2018
Outsourcing in Clinical Trials West Coast: Medical Device Stream Burlingame, CA February 22 nd 2018 Speakers Confirmed: Lian Cunningham, Vice President, Clinical Affairs and Regulatory Affairs, BAROnova
More informationLONDON April Sponsorship & Exhibition Opportunities
LONDON 26-28 April 2017 Sponsorship & Exhibition Opportunities Welcome The International Forum on Quality and Safety in Healthcare will showcase the very best in healthcare improvement from across the
More informationQuestions And Answers To Support The
Questions And Answers To Support The Implementation Of The Pharmacovigilance Legislation - Update This Question and answers section gives advice on regulatory issues in on the interpretation and implementation
More informationThe New EU IVD Regulation & Brexit. Doris-Ann Williams BIVDA
The New EU IVD Regulation & Brexit Doris-Ann Williams BIVDA Agenda 1 2 3 4 5 Some background: Directive vs Regulation Purpose of IVDR Regulatory Changes Impact within the supply chain Required Managerial
More informationUpdate on Real World Evidence Data Collection
Update on Real World Evidence Data Collection STAMP, 10 March 2016 Presented by Dr Peter Arlett EMA An agency of the European Union What is Real-world evidence? Big data = umbrella term describing large
More informationOutsourcing in Clinical Trials Nordics October 30 th 31 st Copenhagen
Outsourcing in Clinical Trials Nordics 2018 October 30 th 31 st Copenhagen 2018 Speakers Confirmed: Magnus Björsne, CEO, AstraZeneca BioVentureHub Mikkel Skovborg, Executive Specialist, NovoNordisk Thomas
More informationMDR Post Market Surveillance
MDR Post Market Surveillance Gert Bos Executive Director & Partner A global leading medical device consultancy group surveillance - SECTION 1 POST-MARKET SURVEILLANCE PMS requires for all products: Post-market
More informationEditor : Francoise SCHLEMMER Date : 09/03/2015 IMDRF, March 9 th 2015 REPORT Present : Hans-Heiner Junker Francoise SCHLEMMER
The European Association Medical Devices - Notified Bodies TEAM-NB A.I.S.B.L. Boulevard Frère Orban 35A B 4000 Liège BELGIQUE Tél.: + 32 (0)4 254 55 88 Fax: + 32 (0)4 254 55 89 E-mail: secretary@team-nb.org
More informationEuropean Society of Cardiology Lessons learned from a decade of engagement
European Society of Cardiology Lessons learned from a decade of engagement Alan G Fraser Chairman, EU Regulatory Affairs Committee fraserag@cf.ac.uk Brussels 21 March 2018 The European Society of Cardiology
More informationChanges to the Regulation of IVDs in Europe. Copyright 2012 BSI. All rights reserved.
Changes to the Regulation of IVDs in Europe Copyright 2012 BSI. All rights reserved. Caution The new regulations are draft and subject to change Further details will be added later pre and post application
More informationOMBU. Ombu Enterprises, LLC Ombu The Operational Excellence Company Ph: Fax: ENTERPRISES, LLC
OMBU ENTERPRISES, LLC Ombu Enterprises, LLC Ombu The Operational Excellence Company Ph: 603-209-0600 Fax: 603-358-3083 OmbuEnterprises@msn.com Docket Number FDA-2010-N-0274 Comments on Oversight of Laboratory
More informationDigital Strategy & Innovation for Medical Affairs
Digital Strategy & Innovation for Medical Affairs February 11-13, 2019 Philadelphia, PA With the Medical function drastically changing in many organizations, this is undoubtedly an exciting time to work
More information8 Steps towards EU-MDR implementation
8 Steps towards EU-MDR implementation Gert Bos Executive director & Partner A global leading medical device consultancy group Europe - Amsterdam (HQ) USA - Boston - San Francisco China Nanjing Copyright
More informationRoles and responsibilities of members and alternates, rapporteur and peer reviewers, experts and observers of the Paediatric Committee (PDCO)
Last revision: 16 September 2010 EMA/537415/2008 Human Medicines Development and Evaluation Roles and responsibilities of members and alternates, rapporteur and peer reviewers, experts and observers of
More informationImpact of the MD/IVD Regulations on Quality Management Systems
Impact of the MD/IVD Regulations on Quality Management Systems Dirk Stynen, Ph. D. President Qarad RMD 2018 Brussels In this presentation: focus on In Vitro Diagnostic Devices... but the same applies to
More informationCommercialising Genomic Research 1-3 October 2018
Course Programme Commercialising Genomic Research 1-3 October 2018 Wellcome Genome Campus Hinxton, Cambridge, UK Monday 1 October 2018 09:30-10:00 Registration with refreshments 10:00-10:30 Introduction
More informationEvent Agenda. Lunch-to-lunch event Get ready for tomorrow Brexit-Symposium in Soest, NRW
Event Agenda Lunch-to-lunch event Get ready for tomorrow Brexit-Symposium 20. 21.11.2018 in Soest, NRW www.brexit-symposium.com Get ready for tomorrow on Brexit! Don t wait until it is too late prepare
More informationNew EU Medical Device Regulations.are you ready? Angela Stokes Senior Director Regulatory Affairs March 2017
New EU Medical Device Regulations.are you ready? Angela Stokes Senior Director Regulatory Affairs March 2017 Agenda Background Notified Bodies Reassessment Classification Changes Technical Documentation
More informationPanel Discussion: European Medical Device Regulations Preparing for the Storm Moderator: Lenita Y. Sims Spears, Senior Quality Consultant/Senior
Panel Discussion: European Medical Device Regulations Preparing for the Storm Moderator: Lenita Y. Sims Spears, Senior Quality Consultant/Senior Regulatory and Compliance Counsel, BioTeknica Panelists:
More informationMedTech Europe Position Paper on Article 50 Negotiations between the European Union and the United Kingdom (Brexit)
MedTech Europe Position Paper on Article 50 Negotiations between the European Union and the United Kingdom (Brexit) EXECUTIVE SUMMARY MedTech Europe the European trade association representing the medical
More informationIndustry perspective on hazardous substances requirements in the Medical Devices sector
Industry perspective on hazardous substances requirements in the Medical Devices sector Speaker: Jean-Marc Abbing (Chair Chemicals Working Group, MedTech Europe) The European trade association for medical
More informationMedical Device Regulation Overview
Medical Device Regulation Overview Dr Haidong Liang, PhD Clifton Medtech Consulting info@cliftonmedtech.com http://cliftonmedtech.com/ What is the issue? Existing EU Directives dating back to the 1990s
More informationHigh Potent Medicines Conference
2nd Annual High Potent Medicines Conference Looking beyond scale-up, containment, regulatory aspects and safety of highly potent compounds Event Overview The HPAPI industry is expanding at a healthy rate
More informationGuide for Marketing Authorisation Holders on Direct Healthcare Professional Communications
Guide for Marketing Authorisation Holders on Direct Healthcare Professional Communications 1 INTRODUCTION A Direct Healthcare Professional Communication (DHPC) aims to promote safe and effective use of
More informationPromoting the Biotechnology Industry in Germany
Positions Promoting the Biotechnology Industry in Germany Germany s biotechnology industry ranks among the most sustainable and forward looking of today s cutting-edge technologies. Biotechnology is about
More information